Please ensure Javascript is enabled for purposes of website accessibility

Here's Why BioNTech Gained 34.8% in June

By Maxx Chatsko – Jul 8, 2020 at 10:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the world's leading coronavirus vaccine efforts reported promising progress.

What happened

Shares of BioNTech (BNTX -1.27%) rose 34.8% last month, according to data provided by S&P Global Market Intelligence. The German biopharma announced progress in efforts to develop a safe and effective vaccine against SARS-CoV-2, the coronavirus that causes COVID-19, with partner Pfizer.

In mid-June, BioNTech announced it had received access to roughly $112 million in debt financing from the European Investment Bank. Two weeks later, the development-stage company announced a $250 million private placement from Temasek, a leading investor in living technologies.

The momentum accelerated on the first day of July, when BioNTech and Pfizer announced early results from a vaccine candidate that suggest it triggers the intended immune responses against SARS-CoV-2 in humans. As of the first week of July, the pharma stock has delivered a year-to-date gain of 105%.

A businessman pointing up and to the right as a rickety wooden arrow displays overhead.

Image source: Getty Images.

So what

BioNTech is developing a pipeline of messenger RNA (mRNA) drug and vaccine candidates. When SARS-CoV-2 began spreading across the globe earlier this year, the company wasted little time deploying its technology platform against the virus. That earned it a lucrative partnership with Pfizer, catapulted it onto the radar of investors, and brought a stream of cash into the business to support its efforts.

The balance sheet received an influx of capital in June, although it was well stocked before the month began. The German biopharma ended March with $495 million in cash. At the time first-quarter 2020 results were announced in mid-May, the company expected to earn an additional $236 million in equity investments from partners Pfizer and Fosun Pharma by the end of June. That's all in addition to the aforementioned June haul comprising $250 million from the private placement from Temasek and access to another $112 million in debt from the European Investment Bank.

Now what

Due to all of the moving parts and dates of fund settlement, it's difficult to precisely estimate how much cash BioNTech might have had at the end of the second quarter, but it's clear the business has the financial flexibility and support from partners to succeed. Now the company only has to deliver successful results in the clinic, manufacture hundreds of millions of doses, and distribute them across the world. That won't be easy, but the business is well positioned to succeed.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
$128.35 (-1.27%) $-1.65
Pfizer Inc. Stock Quote
Pfizer Inc.
$44.08 (-1.10%) $0.49

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.